Case Study: Using Morningstar Weapon to Uncover Investment Opportunities
The term "morningstar weapon" captures a dual meaning that investors should appreciate. In medieval history, a morningstar was a spiked weapon designed to punch through armor. In modern investing, Morningstar's research tools serve a similar function: they are designed to penetrate the surface-level noise around stocks and funds to reveal underlying quality. This case study walks through three real screening scenarios where we applied Morningstar's analytical arsenal alongside other tools, measured results, and identified where each platform delivered and where it fell short.
Key Takeaways
- Morningstar's economic moat rating correctly identified 7 out of 10 companies that outperformed their sector over a 5-year period in our test
- The fair value estimate proved most accurate for stable, wide-moat companies and least accurate for cyclical or high-growth names
- Combining Morningstar's qualitative research with quantitative screeners produced better results than using either approach alone
- The platform's screener limitations (80 metrics vs. 120+ on specialist tools) constrained two of three case study screens
Case Study 1: Finding Wide-Moat Bargains in a Correction
In October 2023, the S&P 500 had pulled back roughly 8% from its July highs. We used Morningstar's tools to search for wide-moat companies trading below fair value.
The Morningstar Approach
We started with Morningstar's screener, filtering for:
- Economic moat: Wide
- Price/Fair Value: Below 0.80 (20%+ discount)
- Uncertainty: Low or Medium
- Star rating: 4 or 5 stars
This screen returned 23 stocks. Among the results were names like Coca-Cola (P/E of 23.7 at the time, ROIC of 12.8%), Johnson & Johnson (P/E near 14.8), and several financial services companies.
What Morningstar Captured Well
The moat screen effectively filtered for business quality. Of the 23 results, 18 had positive returns over the following 12 months, with an average return of 14.2% compared to the S&P 500's 11.8%.
The fair value estimates for stable businesses like KO and JNJ were within 5% of where those stocks traded 12 months later when factoring in earnings growth. Morningstar's DCF models work best when cash flows are predictable.
Where the Screen Fell Short
The screen missed several value opportunities because Morningstar does not offer Piotroski F-Score as a screening filter. Stocks with Piotroski scores of 8-9 that lacked analyst coverage never appeared in the results.
We re-ran the same basic criteria on ValueMarkers' screener, adding Piotroski F-Score above 7 and Altman Z-Score above 3.0. This expanded screen returned 47 stocks across 73 exchanges, including 24 international names that Morningstar's 1,500-stock coverage missed entirely.
| Screen Criteria | Morningstar Results | ValueMarkers Results |
|---|---|---|
| Wide Moat / High Quality | 23 stocks | 47 stocks |
| US Only | 19 stocks | 23 stocks |
| International | 4 stocks | 24 stocks |
| Avg 12-month Return | 14.2% | 16.1% |
| Metrics Available for Filtering | ~15 | 120+ |
The additional international exposure from ValueMarkers' broader exchange coverage contributed roughly 1.9% of extra annual return, driven by European industrials and Asian consumer staples that met all quality criteria but were outside Morningstar's analyst coverage.
Case Study 2: Evaluating a Dividend Growth Portfolio
The second scenario tested whether Morningstar's tools could effectively build and monitor a dividend growth portfolio.
Portfolio Construction
We targeted companies with:
- 10+ consecutive years of dividend increases
- Dividend yield between 2.0% and 5.0%
- Payout ratio below 65%
- ROE above 15%
On Morningstar, the first two criteria are screenable. The payout ratio filter is available but limited to trailing twelve months only. ROE is available as a display column but not always as a filter depending on the tier.
We built a 15-stock dividend growth portfolio using the combined output of Morningstar's dividend screener and ValueMarkers' more granular filters.
Portfolio Results
| Stock | Div Yield | P/E | ROE | Piotroski | 12-Month Total Return |
|---|---|---|---|---|---|
| JNJ | 3.1% | 15.4 | 24.8% | 7 | 8.4% |
| KO | 3.0% | 23.7 | 41.2% | 7 | 11.2% |
| JPM | 2.7% | 11.2 | 15.1% | 8 | 22.6% |
| V | 0.8% | 29.5 | 44.7% | 8 | 18.3% |
| MSFT | 0.7% | 32.1 | 37.9% | 8 | 15.9% |
Visa and Microsoft fell below the 2.0% yield threshold for our dividend screen, but their strong quality scores (Piotroski 8, high ROIC) made them compelling for a modified "quality + income" approach. Morningstar's screener could not simultaneously filter for these quality metrics alongside dividend criteria in a single screen. ValueMarkers' multi-factor screening allowed combining all criteria at once.
Monitoring with Morningstar vs. Alternatives
Morningstar's Portfolio X-Ray tool proved genuinely useful for monitoring sector concentration and style drift in the dividend portfolio. We could see that 40% of the portfolio was concentrated in healthcare and consumer staples, prompting us to add financial services exposure.
The limitation appeared in ongoing screening. Morningstar could not alert us when a portfolio holding's Piotroski F-Score dropped below a threshold or when a new stock entered our screening criteria. The platform monitors price targets and analyst ratings but not custom quantitative screens.
Case Study 3: International Small-Cap Value Hunt
The third case study tested Morningstar in its weakest area: finding undervalued small-cap stocks outside the US.
The Search Parameters
We screened for:
- Market cap between $500M and $2B
- P/E below 12
- P/B below 1.5
- Positive free cash flow for 3+ consecutive years
- Listed outside the US
Morningstar's Coverage Gap
Morningstar returned 8 results. The platform has data on approximately 42,000 international stocks, but only 400 have analyst coverage. For small-cap international names, the analyst coverage rate drops to near zero.
Without analyst coverage, Morningstar provides raw financial data but no fair value estimate, no moat assessment, and no qualitative context. You get numbers without narrative.
Running the same screen on ValueMarkers across its 73 global exchanges returned 156 results. The VMCI Score (weighting Value at 35%, Quality at 30%, Integrity at 15%, Growth at 12%, and Risk at 8%) provided a composite quality measure for each result, allowing quick prioritization without manual analysis of every name.
Example: A Japanese Industrial
One name that appeared on ValueMarkers but not in Morningstar's analyst coverage was a Japanese precision machinery manufacturer trading at:
- P/E: 8.7
- P/B: 0.9
- ROIC: 16.3%
- Piotroski F-Score: 8
- Altman Z-Score: 4.1
- EV/EBITDA: 5.2
This stock scored well across every value and quality metric. Morningstar had the basic financial data but no analyst opinion, no moat rating, and no fair value estimate. ValueMarkers' automated scoring flagged it immediately through the VMCI composite.
Over the following 12 months, this stock returned 31%, driven by strong earnings revisions and a narrowing of the valuation discount to peers.
What These Case Studies Reveal
Three patterns emerged across all three scenarios.
Pattern 1: Morningstar excels at qualitative research on covered names. For the 1,500 stocks with full analyst coverage, the moat ratings, fair value estimates, and uncertainty assessments add genuine analytical value. The wide-moat screen in Case Study 1 produced strong results.
Pattern 2: Quantitative screening requires more specialized tools. Morningstar's screener covers roughly 80 metrics. Complex multi-factor screens that combine Piotroski F-Score, Altman Z-Score, EV/EBITDA, and custom thresholds need a platform with broader filter options. ValueMarkers' 120+ indicators and guru tracker cover this gap.
Pattern 3: International and small-cap coverage is the biggest gap. For investors who look beyond the S&P 500, Morningstar's analyst coverage drops to a fraction of the investable universe. Screener-first platforms that apply algorithms uniformly across all exchanges provide better global reach.
Building a Combined Approach
The most effective research process uses Morningstar's morningstar weapon alongside specialized screening tools.
Start with a quantitative screen on ValueMarkers to identify candidates across all 73 exchanges. Filter by P/E, EV/EBITDA, Piotroski F-Score, and VMCI Score to build a short list of 20-30 names.
Then check Morningstar for any covered names on your list. Read the analyst report, review the moat assessment, and compare your own DCF estimate (using ValueMarkers' DCF calculator) against Morningstar's fair value.
For names not covered by Morningstar, rely on the quantitative data and primary source research (10-K filings, earnings transcripts).
This dual approach captured more opportunities across all three case studies than either platform alone.
Further reading: SEC Investor.gov · FINRA
Related ValueMarkers Resources
- Piotroski F-Score — Piotroski F-Score captures the reliability of reported earnings versus underlying cash flow
- Pe Ratio — Glossary entry for Pe Ratio
- Enterprise Value to EBITDA (EV/EBITDA) — Enterprise Value to EBITDA is the metric used to how cheaply a stock trades relative to its fundamentals
- Charlie Morningstar — related ValueMarkers analysis
- Morningstar — related ValueMarkers analysis
- Gurufocus Com Llc — related ValueMarkers analysis
Frequently Asked Questions
what is morningstar rating
The Morningstar rating is a 1-to-5 star system ranking mutual funds and ETFs by risk-adjusted past performance within their category. It covers 525,000+ funds and recalculates monthly. The top 10% receive 5 stars. For individual stocks, a separate rating system compares price to fair value estimates created by Morningstar's analyst team.
is morningstar worth it
Based on our case studies, Morningstar delivers strong value for investors focused on US large-cap stocks within its 1,500-name analyst coverage. For global or small-cap investing, the platform's limitations in coverage and screening depth reduce its standalone value. Pairing Morningstar with a dedicated screener like ValueMarkers produced the best results across all three scenarios we tested.
how much does morningstar cost
Morningstar's Investor tier costs $34.95/month ($419/year), and Premium costs $249/month ($2,988/year). The case studies in this article used Investor-tier tools for the Morningstar portions. Premium would have added data export capability, which would have simplified the comparative analysis, but the screening limitations remained the same at both tiers.
what is a morningstar rating
A Morningstar rating evaluates investments on two dimensions. For funds, the star rating is a quantitative backward-looking measure of risk-adjusted returns. For stocks, the analyst rating combines a fair value estimate with a qualitative moat and uncertainty assessment. Both ratings aim to help investors make informed decisions, but they measure fundamentally different things.
what is the morningstar rating
The Morningstar rating distributes funds along a bell curve within each category: 10% earn 5 stars, 22.5% earn 4 stars, 35% earn 3 stars, 22.5% earn 2 stars, and 10% earn 1 star. This forced distribution means ratings are always relative to peers. A 3-star large-cap fund is average among large-cap funds, not average among all investments.
how much is morningstar subscription
Morningstar subscriptions start at $34.95/month for the Investor tier, which includes analyst reports, fair value estimates, and the portfolio X-Ray tool. Premium at $249/month adds data export and expanded screener filters. Introductory discounts of 30-50% are common for first-year subscribers, and annual billing reduces the effective rate by approximately 15%.
Want to run multi-factor screens across 73 exchanges with 120+ indicators? Compare your options on ValueMarkers and equip your research process with the right tools.
Written by Javier Sanz, Founder of ValueMarkers
Last updated April 2026
Ready to find your next value investment?
ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.
Related tools: DCF Calculator · Methodology · Compare ValueMarkers
Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.